search
Back to results

the Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria

Primary Purpose

Urinary Tract Infection

Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
phosphomycin
Culture specific antibiotic therapy
Pre-treatment Urine Culture
Antimicrobial sensitivity testing
Post-treatment urine culture
Sponsored by
Ain Shams University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Tract Infection

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Pregnant patients from 13 weeks to 36 weeks gestation.
  2. Pus cells in urine analysis >5/HPF.
  3. ≥ 105 colony-forming units (CFU) per millilitre of the same microorganisms in two consecutive cultures.
  4. No symptoms or sings suggestive of urinary tract infection.

Exclusion Criteria:

  1. Presence of any urinary symptoms as burning micturition, hesitancy
  2. Fever and loin pain.
  3. Diabetes mellitus.
  4. Known to be allergic from any of the antimicrobial ingredients.
  5. Not using any antimicrobial during the course of treatment for any other infection.
  6. Not known to have any congenital urinary anomalies.
  7. If the patient is taking medications that interact with fosfomycin as:

    • Anorexiants (eg, phentermine) or certain sympathomimetics (eg, albuterol, amphetamine, pseudoephedrine) because the risk of their side effects may be increased by fosfomycin.
    • Lithium or tetracyclines because their effectiveness may be decreased by fosfomycin.
    • Metoclopramide because it may decrease fosfomycin's effectiveness.
  8. Impaired kidney functions (creatinine's clearance is <80 ml/min.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Fosfomycin group (FG)

    Culture specific group (CG):

    Arm Description

    Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder. The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form. Response to treatment will be assessed by post-treatment urine culture.

    Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen. Response to treatment will be assessed by post-treatment urine culture.

    Outcomes

    Primary Outcome Measures

    Resolution of asymptomatic bacteriuria
    Decline in colony forming unit (CFU)/mL or absence of bacterial growth after treatment

    Secondary Outcome Measures

    Need for further treatment
    Either extending the course of treatment into 5 or 7 days regimen or changing the antibiotic in case of inadequate initial response.
    Need for further investigations
    Need for urine culture and sensitivity in fosfomycin group in case of inadequate response on empirical treatment.
    Incidence of adverse drug reactions .
    Incidence of adverse drug reactions as nausea, diarrhea, headache, vaginal itching, runny nose, back pain Side effects from other antibiotics in culture and sensitivity group

    Full Information

    First Posted
    June 9, 2016
    Last Updated
    May 24, 2018
    Sponsor
    Ain Shams University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03548129
    Brief Title
    the Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria
    Official Title
    Empirical Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2018
    Overall Recruitment Status
    Unknown status
    Study Start Date
    July 2016 (undefined)
    Primary Completion Date
    July 2018 (Anticipated)
    Study Completion Date
    August 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Ain Shams University

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Urinary tract infections (UTIs) are the most commonly occurring bacterial infections in women, Asymptomatic bacteriuria (AB) is a common complication during pregnancy, with a prevalence of 2-10%. It has been associated with a greater incidence of symptomatic urinary tract infection (UTI), as well as foetal and obstetric complications. Appropriate treatment reduces the incidence of UTI by 80-90%, as well as the risk of a premature birth and low-birth-weight baby Fosfomycin trometamol (Monuril) is approved in numerous countries worldwide, including various European countries and the USA, mainly for the treatment of uncomplicated UTIs
    Detailed Description
    This study aims to compare between the efficacy of empirical use of fosfomycin trometamol and the use of selected antimicrobials according to urinary culture and sensitivity in curing asymptomatic bacteriuria. All women included in the study will be counseled regarding mode of intervention and informed consent will be obtained. All cases will be subjected to complete history taking, routine antenatal examination and investigations including complete blood picture, kidney functions and urine analysis, treatment of genital infection if diagnosed. Routine obstetric ultrasound examination. Patients will be randomized into two groups: Group (A): Fosfomycin group (FG); where all patients will receive empirical 3 gm oral fosfomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder. The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form. Nature: also known as phosphomycin, phosphonomycin, is a broad-spectrum antibiotic, produced by certain Streptomyces species, although it can now be made by chemical synthesis. Trade name: Monuril Company: Zambon, Pharma Con Company, Switzerland Group (B): Culture specific group (CG): where all patients will receive oral antibiotic according to urine culture and sensitivity, oral antibiotics will be given in the form of five days regimen. How the urine sample will be collected? The caregiver will give the patient a sterile cup and lid, and advice her to wash herself completely then clean the perineal area from anterior to posterior by water and in standing position as male begin to urinate then stop urinating put the sterile cup and catch the rest of urine in it. Do not touch the inside of the cup or the lid. Put the lid on the cup. One week after completing the course of treatment all patients included in the study will be subjected to colony count evaluation, to figure out the need for: Urine culture in fosfomycin group in case of inadequate response to treatment and to give antibiotic according. The change of duration or the type of antibiotic in case of inadequate response to initial treatment in the culture group. Outcomes Primary: Resolution of asymptomatic bacteriuria as measured by colony count. Time frame: 1 week Secondary: Side effects of fosfomycin as, nausea, diarrhea, headache, vaginal itching, runny nose, back pain Side effects from other antibiotics in culture and sensitivity group Need for further treatment, either extending the course of treatment into 5 or 7 days regimen or changing the antibiotic in case of inadequate initial response. Need for further investigations, as urine culture and sensitivity for fosfomycin group in case of inadequate response on empirical treatment.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Urinary Tract Infection

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    Investigator
    Allocation
    Randomized
    Enrollment
    88 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Fosfomycin group (FG)
    Arm Type
    Active Comparator
    Arm Description
    Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder. The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form. Response to treatment will be assessed by post-treatment urine culture.
    Arm Title
    Culture specific group (CG):
    Arm Type
    Active Comparator
    Arm Description
    Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen. Response to treatment will be assessed by post-treatment urine culture.
    Intervention Type
    Drug
    Intervention Name(s)
    phosphomycin
    Intervention Description
    Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
    Intervention Type
    Drug
    Intervention Name(s)
    Culture specific antibiotic therapy
    Intervention Description
    Culture-specific antibiotic treatment for 5 days
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    Pre-treatment Urine Culture
    Intervention Description
    Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    Antimicrobial sensitivity testing
    Intervention Description
    Susceptibility of urinary pathogens to various antimicrobials
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    Post-treatment urine culture
    Intervention Description
    Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
    Primary Outcome Measure Information:
    Title
    Resolution of asymptomatic bacteriuria
    Description
    Decline in colony forming unit (CFU)/mL or absence of bacterial growth after treatment
    Time Frame
    1 week
    Secondary Outcome Measure Information:
    Title
    Need for further treatment
    Description
    Either extending the course of treatment into 5 or 7 days regimen or changing the antibiotic in case of inadequate initial response.
    Time Frame
    1 week
    Title
    Need for further investigations
    Description
    Need for urine culture and sensitivity in fosfomycin group in case of inadequate response on empirical treatment.
    Time Frame
    1 week
    Title
    Incidence of adverse drug reactions .
    Description
    Incidence of adverse drug reactions as nausea, diarrhea, headache, vaginal itching, runny nose, back pain Side effects from other antibiotics in culture and sensitivity group
    Time Frame
    1 week

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Pregnant patients from 13 weeks to 36 weeks gestation. Pus cells in urine analysis >5/HPF. ≥ 105 colony-forming units (CFU) per millilitre of the same microorganisms in two consecutive cultures. No symptoms or sings suggestive of urinary tract infection. Exclusion Criteria: Presence of any urinary symptoms as burning micturition, hesitancy Fever and loin pain. Diabetes mellitus. Known to be allergic from any of the antimicrobial ingredients. Not using any antimicrobial during the course of treatment for any other infection. Not known to have any congenital urinary anomalies. If the patient is taking medications that interact with fosfomycin as: Anorexiants (eg, phentermine) or certain sympathomimetics (eg, albuterol, amphetamine, pseudoephedrine) because the risk of their side effects may be increased by fosfomycin. Lithium or tetracyclines because their effectiveness may be decreased by fosfomycin. Metoclopramide because it may decrease fosfomycin's effectiveness. Impaired kidney functions (creatinine's clearance is <80 ml/min.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Mohamed Samy, MD
    Organizational Affiliation
    M Samy
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    the Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria

    We'll reach out to this number within 24 hrs